| Identification | Back Directory | [Name]
Pentanoic acid, 4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxo-, hydrochloride (1:1), (4S)- | [CAS]
2759182-59-5 | [Synonyms]
Neboglamine hydrochloride
Pentanoic acid, 4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxo-, hydrochloride (1:1), (4S)- | [Molecular Formula]
C13H25ClN2O3 | [MOL File]
2759182-59-5.mol | [Molecular Weight]
292.8 |
| Hazard Information | Back Directory | [Uses]
Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research[1]. | [in vivo]
Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats[1].
| Animal Model: | Male Wistar rats[1] | | Dosage: | 20 mg/kg | | Administration: | Subcutaneous injection | | Result: | Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group.
Significantly inhibited phencyclidine-induced hypermobility.
|
| Animal Model: | Male Wistar rats[1] | | Dosage: | 0.3 mg/kg, 3 mg/kg, 30 mg/kg | | Administration: | Oral administration | | Result: | Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg). |
| [References]
[1] Riccardo Chiusaroli, et al. Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat. Pharmacol Res. 2010 May;61(5):430-6. DOI:10.1016/j.phrs.2009.12.010 |
|
|